Gastrointestinal Cancer | Specialty

ReDOS Trial: Optimizing Regorafenib Dosing in metastatic Colorectal Cancer

September 28th 2018

Metastatic Colorectal Cancer: Multiple Lines of Therapy

September 28th 2018

Next-Generation Sequencing and Molecular Subsets in Metastatic Colorectal Cancer

September 28th 2018

The Current Paradigm of Metastatic Colorectal Cancer

September 28th 2018

Dr. Basu on Second-Line Therapy in HCC

September 28th 2018

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Dr. Paulson Discusses Unmet Needs in the Treatment of NETs

September 27th 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Dr. Llovet on Combination Therapy in HCC

September 26th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Dr. Villanueva on Challenges For Liquid Biopsies in HCC

September 25th 2018

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.

Steady Increase in Liver Cancer Death Rates Observed in Adults Aged 25 and Older

September 22nd 2018

A National Center for Health Statistics briefing showed that liver cancer death rates increased significantly for both sexes, with death rates for men 2 to 2.5 times the rate for women from 2000 through 2016.

Dr. Primrose on Adjuvant Capecitabine For Biliary Tract Cancer

September 21st 2018

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

Dr. Shiller on Next-Generation Sequencing in GI Cancers

September 20th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.

Dr. Sapisochin on Neoadjuvant Treatment for HCC

September 20th 2018

Gonzalo Sapisochin, MD, assistant professor of surgery, University of Toronto, discusses neoadjuvant treatment for patients with hepatocellular carcinoma.

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Dr. Finn on Considerations for Lenvatinib in Liver Cancer

September 19th 2018

Richard Finn, MD, associate professor of medicine, University of California, Los Angeles David Geffen School of Medicine, discusses the role of lenvatinib in the treatment of patients with liver cancer.

Immunotherapy Combos May Shape the Future of HCC Therapy

September 17th 2018

The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.

Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

September 16th 2018

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm

September 16th 2018

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

Dr. Lencioni on Assessing Response to HCC Therapy

September 16th 2018

Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

Sangro Says Immunotherapy May Be the Future of HCC Treatment

September 16th 2018

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

Regorafenib Sustains OS Benefit in RESORCE Trial Update

September 16th 2018

Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.